^
Association details:
| Biomarker: | SLC3A2-NRG1 fusion |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | zenocutuzumab (MCLA-128) (HER2 inhibitor, HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor
Published date:
08/17/2022
Excerpt:
A 58-year-old White woman was diagnosed in April 2013 with a stage IIIA grade 2 bifocal infiltrating nonmucinous ductal carcinoma of the right breast...This identified an SLC3A2-NRG1 gene fusion between exon 5 of the SLC3A2 gene and exon 6 of NRG1…Zeno was administered intravenously...After two treatment cycles, a complete metabolic response by positron emission tomography was seen...
DOI:
10.1200/PO.21.00446
